News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

TALEN® Access by Cellectis BioResearch Receives "Most Innovative New Service 2011" Award at Life Science Awards



7/6/2011 7:37:03 AM

PARIS, July 5, 2011 /PRNewswire/ -- Cellectis bioresearch, a subsidiary of Cellectis (Alternext: ALCLS) and specialist in genome customization, has received the "Most Innovative New Service 2011" award from Select Biosciences for their TALEN® Access service offering. TALENs(1) allow for customized gene modifications, providing researchers across multiple disciplines with a powerful and now affordable new tool. This prize was presented at the Life Science Awards preceding the European Lab Automation conference held in HamburgJune 30 and July 1, 2011.

Each year the Life Science Awards celebrate the best of the industry's achievements worldwide. The awards are judged by a panel of international industrial and academic experts.

"We are very honored to receive this award. It rewards well our team's tremendous work in coming up with such an extremely high quality offer at an affordable price, only a few months after having acquired the technology," stated Dr. Luc Selig, VP Sales and Marketing at Cellectis bioresearch.

"We are the first to market TALEN® and are bringing in new clients every day," added Marc Le Bozec, CEO of Cellectis bioresearch. "Our ambition is to convert biology researchers around the world to genome customization. This community of 3 million is now exploring this completely new approach that allows them to better do things they were already doing, but most importantly opens up so many new possibilities. We estimate the market potential to be in the millions of euro within 10 years."

Today, TALEN® Access is paired with individualized project management support to better meet the needs of Cellectis bioresearch clients.

(1) TALEN: Transcription Activator-Like Effector Nuclease

About Cellectis bioresearch

Cellectis bioresearch was incorporated as a subsidiary of Cellectis (Alternext: ALCLS) in June 2008. It provides life science researchers with ready- and easy-to-use tools for genome customization. These tools, based on sequence specific nucleases, enable the engineering of cells with optimized features for drug discovery, protein production and gene functional studies. The genome customization products and services can be purchased online from www.cellectis-bioresearch.com. Check the website for more information.

Follow Cellectis bioresearch on twitter : http://twitter.com/genegineer

About Cellectis

Cellectis improves life by applying its genome engineering expertise to a broad range of applications, including agriculture, bioresearch and human therapeutics. Cellectis is listed on the NYSE-Euronext Alternext market (code: ALCLS) in Paris.

For further information about Cellectis, visit our website at: www.cellectis.com

Follow Cellectis on twitter : http://twitter.com/cellectis

Disclaimer

This press release and the information contained herein do not constitute an offer to sell or subscribe, or a solicitation of an offer to buy or subscribe, for shares in Cellectis in any country. This press release contains forward-looking statements that relate to the Company s objectives based on the current expectations and assumptions of the Company's management only and involve risk and uncertainties that could cause the Company to fail to achieve the objectives expressed by the forward-looking statements.

SOURCE Cellectis


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES